News | January 23, 2024
Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
The company has posted net profit of Rs.33.57 crores for the 9 Months period ended December 31, 2023
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
Subscribe To Our Newsletter & Stay Updated
